1887

Microbiology Society logo

Volume 169, Issue 7

Preclinical testing of antimicrobials for cystic fibrosis lung infections: current needs and future priorities Open Access

Abstract

A workshop was held by the PIPE-CF strategic research centre to consider preclinical testing of antimicrobials for cystic fibrosis (CF). The workshop brought together groups of people from the CF community to discuss current challenges and identify priorities when developing CF therapeutics. This paper summarizes the key points from the workshop from the different sessions, including talks given by presenters on the day and round table discussions. Currently, it is felt that there is a large disconnect throughout the community, with communication between patients, clinicians and researchers being the main issue. This leads to little consideration being given to factors such as treatment regimes, routes of administration and side effects when developing new therapies, that could alter the day-to-day lifestyles of people living with CF. Translation of numerical data that are obtained in the laboratory to successful outcomes of clinical trials is also a key challenge facing researchers today. Laboratory assays in preclinical testing involve basing results on bacterial clearance and decrease in viable cells, when these are not factors that are considered when determining the success of a treatment in the clinic. However, there are several models currently in development that seek to tackle some of these issues, such as the organ-on-a-chip technology and adaptation of a hollow-fibre model, as well as the development of media that aim to mimic the niche environments of a CF respiratory tract. It is hoped that by summarizing these opinions and discussing current research, the communication gap between groups can begin to close.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): CF community , cystic fibrosis and model development
Funding
This study was supported by the:
  • Cystic Fibrosis Foundation (Award SRC022)
    • Principle Award Recipient: NotApplicable
  • Cystic Fibrosis Trust (Award SRC022)
    • Principle Award Recipient: NotApplicable
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.001361
2023-07-10
2024-05-13
Loading full text...

Full text loading...

/deliver/fulltext/micro/169/7/mic001361.html?itemId=/content/journal/micro/10.1099/mic.0.001361&mimeType=html&fmt=ahah

References

  1. Crull MR, Somayaji R, Ramos KJ, Caldwell E, Mayer-Hamblett N et al. Changing rates of chronic Pseudomonas aeruginosa infections in cystic fibrosis: a population-based cohort study. Clin Infect Dis 2018; 67:1089–1095 [View Article] [PubMed]
     [Google Scholar]
  2. CF Trust Antibiotic treatments for cystic fibrosis; 2009 https://www.cysticfibrosis.org.uk/sites/default/files/2020-11/Anitbiotic%20Treatment.pdf accessed 6 February 2023
  3. James Lind Alliance Cystic Fibrosis Refresh Top 10 priorities (priority setting in association with the JLA; 2022 https://www.jla.nihr.ac.uk/priority-setting-partnerships/cystic-fibrosis/top-10-priorities.htm accessed 6 February 2023
  4. Trials Tracker; 2022 https://www.cysticfibrosis.org.uk/get-involved/clinical-trials/trialstracker accessed 6 February 2023
  5. Barton TE, Frost F, Fothergill JL, Neill DR. Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis. J Med Microbiol 2022; 71: [View Article] [PubMed]
     [Google Scholar]
  6. Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR et al. Developing inhaled antibiotics in cystic fibrosis: current challenges and opportunities. Ann Am Thorac Soc 2019; 16:534–539 [View Article] [PubMed]
     [Google Scholar]
  7. Wright MFA, Bush A, Carr SB. Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis. Paediatr Respir Rev 2018; 27:9–12 [View Article] [PubMed]
     [Google Scholar]
  8. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299–323 [View Article] [PubMed]
     [Google Scholar]
  9. Mahenthiralingam E, Weiser R, Floto RA, Davies JC, Fothergill JL. Selection of relevant bacterial strains for novel therapeutic testing: a guidance document for priority cystic fibrosis lung pathogens. Curr Clin Micro Rpt 2022; 9:33–45 [View Article]
     [Google Scholar]
  10. Zlosnik JEA, Henry DA, Hird TJ, Hickman R, Campbell M et al. Epidemiology of Burkholderia infections in people with cystic fibrosis in Canada between 2000 and 2017. Ann Am Thorac Soc 2020; 17:1549–1557 [View Article] [PubMed]
     [Google Scholar]
  11. Freschi L, Vincent AT, Jeukens J, Emond-Rheault J-G, Kukavica-Ibrulj I et al. The Pseudomonas aeruginosa pan-genome provides new insights on its population structure, horizontal gene transfer, and pathogenicity. Genome Biol Evol 2019; 11:109–120 [View Article] [PubMed]
     [Google Scholar]
  12. Parks DH, Chuvochina M, Chaumeil P-A, Rinke C, Mussig AJ et al. A complete domain-to-species taxonomy for bacteria and archaea. Nat Biotechnol 2020; 38:1098 [View Article] [PubMed]
     [Google Scholar]
  13. Morales-Ruíz L-M, Rodríguez-Cisneros M, Kerber-Díaz J-C, Rojas-Rojas F-U, Ibarra JA et al. Burkholderia orbicola sp. nov., a novel species within the Burkholderia cepacia complex. Arch Microbiol 2022; 204:178 [View Article] [PubMed]
     [Google Scholar]
  14. Wallner A, King E, Ngonkeu ELM, Moulin L, Béna G. Genomic analyses of Burkholderia cenocepacia reveal multiple species with differential host-adaptation to plants and humans. BMC Genomics 2019; 20:803 [View Article] [PubMed]
     [Google Scholar]
  15. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381:1551–1560 [View Article] [PubMed]
     [Google Scholar]
  16. Bryant JM, Brown KP, Burbaud S, Everall I, Belardinelli JM et al. Stepwise pathogenic evolution of Mycobacterium abscessus. Science 2021; 372:eabb8699 [View Article] [PubMed]
     [Google Scholar]
  17. Zheng F, Fu F, Cheng Y, Wang C, Zhao Y et al. Organ-on-a-chip systems: microengineering to biomimic living systems. Small 2016; 12:2253–2282 [View Article] [PubMed]
     [Google Scholar]
  18. Ogden HL, Kim H, Wikenheiser-Brokamp KA, Naren AP, Mun KS et al. Cystic fibrosis human organs-on-a-chip. Micromachines 2021; 12:747 [View Article] [PubMed]
     [Google Scholar]
  19. Plebani R, Potla R, Soong M, Bai H, Izadifar Z et al. Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip. J Cyst Fibros 2022; 21:606–615 [View Article] [PubMed]
     [Google Scholar]
  20. Schneider MR, Oelgeschlaeger M, Burgdorf T, van Meer P, Theunissen P et al. Applicability of organ-on-chip systems in toxicology and pharmacology. Crit Rev Toxicol 2021; 51:540–554 [View Article] [PubMed]
     [Google Scholar]
  21. Shrestha J, Razavi Bazaz S, Aboulkheyr Es H, Yaghobian Azari D, Thierry B et al. Lung-on-a-chip: the future of respiratory disease models and pharmacological studies. Crit Rev Biotechnol 2020; 40:213–230 [View Article] [PubMed]
     [Google Scholar]
  22. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E et al. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp 2012e3857 [View Article] [PubMed]
     [Google Scholar]
  23. Palmer KL, Kelli L, Whiteley M. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 2007; 189:8079–8087 [View Article] [PubMed]
     [Google Scholar]
  24. Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci 2015; 112:4110–4115 [View Article] [PubMed]
     [Google Scholar]
  25. Cornforth DM, Diggle FL, Melvin JA, Bomberger JM, Whiteley M. Quantitative framework for model evaluation in microbiology research using Pseudomonas aeruginosa and cystic fibrosis infection as a test case. mBio 2020; 11:e03042-19 [View Article] [PubMed]
     [Google Scholar]
  26. Ruhluel D, O’Brien S, Fothergill JL, Neill DR. Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health. F1000Res 2022; 11:1007 [View Article] [PubMed]
     [Google Scholar]
  27. Eberhard A, Burlingame AL, Eberhard C, Kenyon GL, Nealson KH et al. Structural identification of autoinducer of Photobacterium fischeri luciferase. Biochemistry 1981; 20:2444–2449 [View Article] [PubMed]
     [Google Scholar]
  28. Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V et al. Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients. Antimicrob Agents Chemother 2018; 62:e01150-18 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.001361
Loading

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error